Lykos CEO Amy Emerson leaves after failed FDA approval bid
- CEO steps down from troubled Ecstasy-drug company Lykos Therapeutics
- FDA rejected the application for ecstasy-based therapy
- Interim CEO Michael Mullette takes over
- Company cuts about three quarters of its staff
- Veterans’ organizations supported the therapy
- FDA probe widened due to side effects concerns
Amy Emerson, the CEO of Lykos Therapeutics, has stepped down from her role following the company’s unsuccessful bid for FDA approval of its ecstasy-based therapy. The Food and Drug Administration rejected the application due to insufficient evidence proving the treatment’s safety and efficacy for post-traumatic stress disorder. Lykos Therapeutics will be led by interim CEO Michael Mullette, who previously worked at Moderna and Sanofi. The company has cut about three quarters of its staff and is planning to resubmit its drug application after conducting another clinical study. Veterans’ organizations supported the therapy, but the FDA raised concerns over serious side effects in study subjects and therapists offering ‘underground’ MDMA sessions.
Factuality Level: 7
Factuality Justification: The article provides accurate and objective information about the CEO change in Lykos Therapeutics and the FDA’s rejection of their MDMA-based therapy application. It also mentions the intended use for the treatment and the company’s plans to resubmit its drug for approval after conducting another clinical study. However, it could be more concise and avoid speculation about potential side effects.
Noise Level: 4
Noise Justification: The article provides relevant information about the CEO stepping down from Lykos Therapeutics and the FDA’s rejection of their MDMA-based therapy application. However, it could benefit from more in-depth analysis of the implications of this decision on the field of psychedelic therapies and the future of similar treatments.
Public Companies: Moderna (MRNA), Sanofi (SNY), Compass Pathways (CMPS)
Private Companies: Lykos Therapeutics
Key People: Amy Emerson (CEO), Michael Mullette (Interim CEO)
Financial Relevance: Yes
Financial Markets Impacted: Lykos Therapeutics’ stock price and the psychedelic drugs market
Financial Rating Justification: The article discusses the resignation of the CEO of Lykos Therapeutics, a company involved in the development of MDMA-based therapy for post-traumatic stress disorder. This impacts financial markets as it affects the company’s stock price and the broader psychedelic drugs market.
Presence Of Extreme Event: No
Nature Of Extreme Event: No
Impact Rating Of The Extreme Event: No
Extreme Rating Justification: There is no extreme event mentioned in the article.
Move Size: No market move size mentioned.
Sector: Healthcare
Direction: Down
Magnitude: Large
Affected Instruments: Stocks
www.wsj.com 
